



RESEARCH TOPIC CLI26

Personalization of therapies for inflammatory cutaneous diseases: a patient-centred analysis of clinical trials and real-world registries with a focus on comorbidities

Clinical Unit name

Dermatology Unit
IRCCS – Humanitas Research Hospital

Supervisor

Antonio Costanzo
antonio.costanzo@hunimed.eu

Abstract

The introduction of biologics has dramatically changed the treatment of patients with inflammatory skin diseases. However, a personalized treatment profile for each patient has not been well defined yet, considering the cardio-metabolic comorbidities associated with psoriasis, the Th2-mediated pathologies related to atopic dermatitis and alopecia areata, or the syndromic forms of hidradenitis suppurativa. The aim of this project will be the definition of the different patient profiles, with a focus on comorbidities, in order to identify the most suitable drug for each phenotype. Moreover, we will try to assess the possible beneficial impact of these treatments also on the comorbidities associated with the underlying dermatosis. These evaluations will be conducted by analyzing clinical trials and real-world registries. Finally, we will try to promote awareness of inflammatory skin diseases and their impact on health, highlighting the comorbidities associated with each of them.

Scientific references

1. Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. *Int J Mol Sci.* 2020;21(5):1690. Published 2020 Mar 1. doi:10.3390/ijms21051690
2. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence?. *Br J Dermatol.* 2020;182(4):840-848. doi:10.1111/bjd.18245
3. Menter MA, Mehta NN, Lebwohl MG, et al. The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2). *J Drugs Dermatol.* 2020;19(8):703-708. doi:10.36849/JDD.2020.5337
4. Merola JF, McInnes IB, Deodhar AA, et al. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. *Rheumatol Ther.* 2022;9(3):935-955

5. Gargiulo L, Piscazzi F, Ibba L, et al. Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience. J Dermatolog Treat. 2023;34(1):2192840. doi:10.1080/09546634.2023.2192840
6. Kim J, Ahn K. Atopic dermatitis endotypes: knowledge for personalized medicine. Curr Opin Allergy Clin Immunol. 2022;22(3):153-159. doi:10.1097/ACI.0000000000000820
7. Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092-1101.

Type of contract

Contract for continuative and coordinated service of at least € 26.000 activated Istituto Clinico Humanitas. This sum is subject to IRPEF income tax.

Contratto collaborazione coordinata e continuativa (cococo) pari ad almeno € 26.000 annui lordi attivato da Istituto Clinico Humanitas. Importo soggetto a tassazione IRPEF.